Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Stephen G. Divers"'
Autor:
Vassiliki A. Papadimitrakopoulou, Richard B. Lanman, Justin I. Odegaard, Daniel Dix, Miguel A. Villalona-Calero, Karen L. Reckamp, Stephen G. Divers, Davey B. Daniel, Victoria M. Raymond, Ray D. Page, Natasha B. Leighl
Supplementary Table 1: Detailed assessment of each of the 282 patients. For each of the 282 patients, genomic testing outcome for each modality and each of the eight genomic biomarkers is outlined, as well as KRAS and tissue assessed PD-L1 expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4712b23d27b0a31df6948681435e10a9
https://doi.org/10.1158/1078-0432.22472013.v1
https://doi.org/10.1158/1078-0432.22472013.v1
Autor:
Vassiliki A. Papadimitrakopoulou, Richard B. Lanman, Justin I. Odegaard, Daniel Dix, Miguel A. Villalona-Calero, Karen L. Reckamp, Stephen G. Divers, Davey B. Daniel, Victoria M. Raymond, Ray D. Page, Natasha B. Leighl
Supplementary Table Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::165bed7fa3af99fe213112e50a7b2c8f
https://doi.org/10.1158/1078-0432.22472010
https://doi.org/10.1158/1078-0432.22472010
Autor:
Vassiliki A. Papadimitrakopoulou, Richard B. Lanman, Justin I. Odegaard, Daniel Dix, Miguel A. Villalona-Calero, Karen L. Reckamp, Stephen G. Divers, Davey B. Daniel, Victoria M. Raymond, Ray D. Page, Natasha B. Leighl
Purpose:Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended by profes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61681bc5a7d80341388c4b6bb86e46a
https://doi.org/10.1158/1078-0432.c.6528081.v1
https://doi.org/10.1158/1078-0432.c.6528081.v1
Autor:
Emma G. Sturgill, Jaya Srivastava, Jessica Correia, Cooper Schumacher, Daniel Luckett, Cesar A. Perez, Judy S. Wang, Stephen G. Divers, Babar Bashir, Jennifer Johnson, Valerie M. Jansen, Andrew J. McKenzie, David R. Spigel
Publikováno v:
Cancer Research. 83:921-921
Neuregulin-1 (encoded by NRG1) serves as a ligand for ERBB3 and can lead to dysregulated cellular proliferation in cases of NRG1 fusions. The reported incidence of NRG1 fusions in solid tumors is ~0.1-0.3% with enrichment in invasive mucinous adenoca
Autor:
Emma G. Sturgill, Sahiti Kolli, Kavanya Feustel, Daniel Luckett, Carissa Jones, Marilyn Elaine Holt, Annastasia Hyde, Suzanne Fields Jones, Cesar Augusto Perez, Judy S. Wang, Stephen G. Divers, Meredith Pelster, Jason Timothy Henry, David R. Spigel, Howard A. Burris III, Andrew Jacob McKenzie
Publikováno v:
Journal of Clinical Oncology. 41:738-738
738 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating diagnosis with an overall 5-year survival rate of ~10%. Therapies targeting KRAS G12D, a prevalent molecular driver of PDAC, represent an active area of investigation with
Autor:
Richard B Lanman, Stefanie A Mortimer, Oliver A Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A Collisson, Stephen G Divers, Dave S B Hoon, E Scott Kopetz, Jeeyun Lee, Petros G Nikolinakos, Arthur M Baca, Bahram G Kermani, Helmy Eltoukhy, AmirAli Talasaz
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140712 (2015)
Next-generation sequencing of cell-free circulating solid tumor DNA addresses two challenges in contemporary cancer care. First this method of massively parallel and deep sequencing enables assessment of a comprehensive panel of genomic targets from
Externí odkaz:
https://doaj.org/article/133fc4af39b34633abd205b896147ca3
Autor:
Miguel A. Villalona-Calero, Natasha B. Leighl, Leylah Drusbosky, Stephen G. Divers, Hiba I. Dada, Karen L. Reckamp, Richard B. Lanman, Davey B. Daniel, Daniel Dix, Vassiliki A. Papadimitrakopoulou, Victoria M. Raymond, Justin I. Odegaard, Ray D. Page
Publikováno v:
Clinical lung cancer. 23(1)
Background Somatic genomic testing is recommended by numerous expert guidelines to inform targeted therapy treatment for patients with advanced nonsquamous non-small cell lung cancer (aNSCLC). The NILE study was a prospective observational study that
Autor:
Davey B. Daniel, Stephen G. Divers, Miguel A. Villalona-Calero, Daniel Dix, Richard B. Lanman, Natasha B. Leighl, Ray D. Page, Vassiliki A. Papadimitrakopoulou, Victoria M. Raymond, Justin I. Odegaard, Karen L. Reckamp
Publikováno v:
Clinical Cancer Research. 25:4691-4700
Purpose:Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended by profes
Autor:
Karen L. Reckamp, Hiba I. Dada, Leylah Drusbosky, Miguel A. Villalona-Calero, Davey B. Daniel, Vassiliki A. Papadimitrakopoulou, Victoria M. Raymond, Ray D. Page, Justin I. Odegaard, Natasha B. Leighl, Richard B. Lanman, Stephen G. Divers
Publikováno v:
Journal of Clinical Oncology. 39:9027-9027
9027 Background: Somatic genomic testing is recommended by numerous expert guidelines to inform targeted therapy treatment for patients with advanced lung adenocarcinoma (aLUAD). The NILE study was a prospective observational study that demonstrated
Autor:
Eric A. Collisson, Stefanie Mortimer, Amir Ali Talasaz, Rene Lopez, Petros Nikolinakos, Bahram G. Kermani, Dragan Sebisanovic, Helmy Eltoukhy, Arthur Baca, Dave S.B. Hoon, E. Scott Kopetz, Stephen G. Divers, Oliver A. Zill, Richard B. Lanman, Jeeyun Lee, Sibel Blau
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140712 (2015)
PLoS ONE
PLoS ONE
Next-generation sequencing of cell-free circulating solid tumor DNA addresses two challenges in contemporary cancer care. First this method of massively parallel and deep sequencing enables assessment of a comprehensive panel of genomic targets from